GLP-1 Market
LLY $1157.49 ▲ +1.3% NVO $37.53 ▼ -0.0% PFE $27.50 ▲ +0.3% VKTX $28.38 ▼ -3.1% KLRA $10.83 ▼ -0.1% GPCR $27.47 ▼ -0.4% RHHBY $52.55 ▲ +0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Treatment with iron

Company
University of Rochester
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 7, 2026

Trial details
  • Completed NCT NCT02271997

    Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass

    Not yet reported Rijnstate Hospital 120 participants Est. completion 2017-06-06 3 sites
    Other conditions: Iron Deficiency
    View official trial listing →
  • Completed NCT NCT02278341

    Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis

    Not yet reported Astellas Pharma Europe B.V. 838 participants Est. completion 2018-07-06 143 sites Stand-alone
    Other conditions: Anemia, End Stage Renal Disease (ESRD)
    View official trial listing →
  • Completed NCT NCT02390921

    The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron

    Not yet reported Hospital Universitari Vall d'Hebron Research Institute 40 participants Est. completion 2015-11 1 site
    Other conditions: Liposomated Iron, Y-de-Roux Gastric By-Pass, Parenteral Iron Therapy
    View official trial listing →
  • Completed NCT NCT02492672

    Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease

    American Regent, Inc. 50 participants Est. completion 2018-12 9 sites
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT02707757

    Treatment Response in Dialysis Anaemia

    Not yet reported Imperial College Healthcare NHS Trust 197 participants Est. completion 2017-04 2 sites
    Other conditions: Anaemia, Haemodialysis
    View official trial listing →
  • Suspended NCT NCT03193073

    Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient

    Not yet reported Omnia Mohammed Hashem 80 participants Est. completion 2020-12-01 1 site
    Chronic kidney disease Other conditions: Endothelial Dysfunction, Left Ventricular Hypertrophy, Fibroblast Growth Factor 23
    View official trial listing →
  • Completed NCT NCT03237065

    Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

    Not yet reported Pharmacosmos A/S 122 participants Est. completion 2018-05-29 15 sites
    Other conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
    View official trial listing →
  • Completed NCT NCT03238911

    Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

    Not yet reported Pharmacosmos A/S 123 participants Est. completion 2018-06-19 16 sites
    Other conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
    View official trial listing →
  • Completed NCT NCT03466983

    A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

    Not yet reported Pharmacosmos A/S 97 participants Est. completion 2020-05-25 1 site
    Other conditions: IBD
    View official trial listing →
  • Completed NCT NCT04318405

    Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).

    Pierre Fabre Pharma AG 327 participants Est. completion 2022-11-30 21 sites
    Other conditions: Iron-Deficiency Anemia, Iron-Deficiency
    View official trial listing →
  • Status unknown NCT NCT04491916

    Iron Therapy in Patients With End-Stage Renal Disease

    Not yet reported Kaohsiung Medical University Chung-Ho Memorial Hospital 200 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: End-stage Renal Disease, Anemia, Cardiovascular Risk Factor, Inflammation
    View official trial listing →
  • Status unknown NCT NCT05221957

    Effects of Preoperative Correction of Anemia With Intravenously Iron in Colorectal Cancer Patients.

    Not yet reported Zealand University Hospital 200 participants Est. completion 2023-12 Stand-alone
    Other conditions: Colorectal Cancer, Anemia, Iron-deficiency
    View official trial listing →
  • Withdrawn NCT NCT07287371

    Sucrosomial Vs Intravenous Iron for Preoperative Anemia

    Not yet reported University of Rochester Est. completion 2027-06-30 1 site
    Other conditions: Anemia, Iron Deficiency Anemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Treatment with iron, Treatment with intravenous iron

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.